Synthesis and Bioactivities of Kanamycin B-Derived Cationic Amphiphiles

Journal of Medicinal Chemistry

Volumn 58, Issue 23, 2015, Pages 9124-9132

  Fosso, Marina Y ^a   Shrestha, Sanjib K ^a   Green, Keith D ^a   Garneau Tsodikova, Sylvie ^a  

^a University of Kentucky   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALIPHATIC COMPOUND; AMINOGLYCOSIDE DERIVATIVE; AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CARBON 14; GLYCEROPHOSPHOLIPID; GRAMICIDIN; KANAMYCIN B; POSACONAZOLE; STEROL DERIVATIVE; SULFIDE; SULFONE DERIVATIVE; ANTIINFECTIVE AGENT; KANAMYCIN; SURFACTANT;

ANIMAL CELL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ARTICLE; ASPERGILLUS NIDULANS; BACILLUS SUBTILIS; BACTERIAL CLEARANCE; BACTERIAL GROWTH; BACTERIAL STRAIN; CANDIDA ALBICANS; CELL DEATH; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY; CYTOTOXICITY ASSAY; DRUG DESIGN; DRUG PENETRATION; DRUG POTENCY; DRUG POTENTIATION; DRUG SCREENING; DRUG SYNTHESIS; ENZYME ACTIVITY; FUNGAL MEMBRANE; FUNGAL STRAIN; FUNGUS ISOLATION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; GROWTH INHIBITION; HEMOLYSIS; HYDROPHOBICITY; IC50; IN VITRO STUDY; INCUBATION TEMPERATURE; INHIBITORY CONCENTRATION; KLEBSIELLA PNEUMONIAE; LISTERIA MONOCYTOGENES; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOBACTERIUM SMEGMATIS; NONHUMAN; NUCLEOPHILICITY; OXIDATION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; VANCOMYCIN RESISTANT ENTEROCOCCUS; ANALOGS AND DERIVATIVES; ANIMAL; BACTERIAL INFECTIONS; BACTERIUM; CELL LINE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; FUNGUS; HUMAN; MYCOSES; SYNTHESIS;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; CELL LINE; CELL SURVIVAL; DRUG DESIGN; DRUG RESISTANCE, MICROBIAL; FUNGI; HEMOLYSIS; HUMANS; KANAMYCIN; MICE; MYCOSES; SURFACE-ACTIVE AGENTS;

EID: 84949792852     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b01375     Document Type: Article

References (48)

1. Fosso, M. Y.; Li, Y.; Garneau-Tsodikova, S. New trends in aminoglycosides use MedChemComm 2014, 5, 1075-1091 10.1039/C4MD00163J
2. Houghton, J. L.; Green, K. D.; Chen, W.; Garneau-Tsodikova, S. The future of aminoglycosides: the end or renaissance? ChemBioChem 2010, 11, 880-902 10.1002/cbic.200900779
3. Lee, H. B.; Kim, Y.; Kim, J. C.; Choi, G. J.; Park, S. H.; Kim, C. J.; Jung, H. S. Activity of some aminoglycoside antibiotics against true fungi, Phytophthora and Pythium species J. Appl. Microbiol. 2005, 99, 836-843 10.1111/j.1365-2672.2005.02684.x
4. Mahl, D. L.; de Jesus, F. P.; Loreto, E.; Zanette, R. A.; Ferreiro, L.; Pilotto, M. B.; Alves, S. H.; Santurio, J. M. In vitro susceptibility of Pythium insidiosum isolates to aminoglycoside antibiotics and tigecycline Antimicrob. Agents Chemother. 2012, 56, 4021-4023 10.1128/AAC.00073-12
5. Knight, S. C.; Anthony, V. M.; Brady, A. M.; Greenland, A. J.; Heaney, S. P.; Murray, D. C.; Powell, K. A.; Schulz, M. A.; Spinks, C. A.; Worthington, P. A.; Youle, D. Rationale and perspectives on the development of fungicides Annu. Rev. Phytopathol. 1997, 35, 349-372 10.1146/annurev.phyto.35.1.349
6. Strange, R. N.; Scott, P. R. Plant disease: a threat to global food security Annu. Rev. Phytopathol. 2005, 43, 83-116 10.1146/annurev.phyto.43.113004.133839
7. Fisher, M. C.; Henk, D. A.; Briggs, C. J.; Brownstein, J. S.; Madoff, L. C.; McCraw, S. L.; Gurr, S. J. Emerging fungal threats to animal, plant and ecosystem health Nature 2012, 484, 186-194 10.1038/nature10947
8. Falci, D. R.; Pasqualotto, A. C. Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections Infect. Drug Resist. 2013, 6, 163-174 10.2147/IDR.S51340
9. Sheehan, D. J.; Hitchcock, C. A.; Sibley, C. M. Current and emerging azole antifungal agents Clin. Microbiol. Rev. 1999, 12, 40-79
10. Dolton, M. J.; McLachlan, A. J. Optimizing azole antifungal therapy in the prophylaxis and treatment of fungal infections Curr. Opin. Infect. Dis. 2014, 27, 493-500 10.1097/QCO.0000000000000103
11. Chang, C. W.; Fosso, M.; Kawasaki, Y.; Shrestha, S.; Bensaci, M. F.; Wang, J.; Evans, C. K.; Takemoto, J. Y. Antibacterial to antifungal conversion of neamine aminoglycosides through alkyl modification. Strategy for reviving old drugs into agrofungicides J. Antibiot. 2010, 63, 667-672 10.1038/ja.2010.110
12. Fosso, M.; AlFindee, M. N.; Zhang, Q.; Nziko Vde, P.; Kawasaki, Y.; Shrestha, S. K.; Bearss, J.; Gregory, R.; Takemoto, J. Y.; Chang, C. W. Structure-activity relationships for antibacterial to antifungal conversion of kanamycin to amphiphilic analogues J. Org. Chem. 2015, 80, 4398-4411 10.1021/acs.joc.5b00248
13. Chang, C. W.; Takemoto, J. Y. Antifungal amphiphilic aminoglycosides MedChemComm 2014, 5, 1048-1057 10.1039/C4MD00078A
14. Shrestha, S. K.; Chang, C. W.; Meissner, N.; Oblad, J.; Shrestha, J. P.; Sorensen, K. N.; Grilley, M. M.; Takemoto, J. Y. Antifungal amphiphilic aminoglycoside K20: bioactivities and mechanism of action Front. Microbiol. 2014, 5, 671 10.3389/fmicb.2014.00671
15. Shrestha, S. K.; Fosso, M. Y.; Green, K. D.; Garneau-Tsodikova, S. Amphiphilic tobramycin analogues as antibacterial and antifungal agents Antimicrob. Agents Chemother. 2015, 59, 1565-1570 10.1128/AAC.00229-15
16. Shrestha, S.; Grilley, M.; Fosso, M. Y.; Chang, C. W.; Takemoto, J. Y. Membrane lipid-modulated mechanism of action and non-cytotoxicity of novel fungicide aminoglycoside FG08 PLoS One 2013, 8, e73843 10.1371/journal.pone.0073843
17. Corcoran, J. W.; Hahn, F. E. Mechanism of Action of Antimicrobial and Antitumor Agents; Springer Science & Business Media: New York, 2012; p 744.
18. Zhang, J.; Chiang, F. I.; Wu, L.; Czyryca, P. G.; Li, D.; Chang, C. W. Surprising alteration of antibacterial activity of 5-modified neomycin against resistant bacteria J. Med. Chem. 2008, 51, 7563-7573 10.1021/jm800997s
19. Bera, S.; Zhanel, G. G.; Schweizer, F. Design, synthesis, and antibacterial activities of neomycin-lipid conjugates: polycationic lipids with potent Gram-positive activity J. Med. Chem. 2008, 51, 6160-6164 10.1021/jm800345u
20. Hanessian, S.; Szychowski, J.; Adhikari, S. S.; Vasquez, G.; Kandasamy, P.; Swayze, E. E.; Migawa, M. T.; Ranken, R.; Francois, B.; Wirmer-Bartoschek, J.; Kondo, J.; Westhof, E. Structure-based design, synthesis, and A-site rRNA cocrystal complexes of functionally novel aminoglycoside antibiotics: C2 ether analogues of paromomycin J. Med. Chem. 2007, 50, 2352-2369 10.1021/jm061200+
21. Zhang, J.; Keller, K.; Takemoto, J. Y.; Bensaci, M.; Litke, A.; Czyryca, P. G.; Chang, C. W. Synthesis and combinational antibacterial study of 5-modified neomycin J. Antibiot. 2009, 62, 539-544 10.1038/ja.2009.66
22. Hanessian, S.; Pachamuthu, K.; Szychowski, J.; Giguere, A.; Swayze, E. E.; Migawa, M. T.; Francois, B.; Kondo, J.; Westhof, E. Structure-based design, synthesis and A-site rRNA co-crystal complexes of novel amphiphilic aminoglycoside antibiotics with new binding modes: a synergistic hydrophobic effect against resistant bacteria Bioorg. Med. Chem. Lett. 2010, 20, 7097-7101 10.1016/j.bmcl.2010.09.084
23. Bera, S.; Zhanel, G. G.; Schweizer, F. Antibacterial activities of aminoglycoside antibiotics-derived cationic amphiphiles. Polyol-modified neomycin B-, kanamycin A-, amikacin-, and neamine-based amphiphiles with potent broad spectrum antibacterial activity J. Med. Chem. 2010, 53, 3626-3631 10.1021/jm1000437
24. Ouberai, M.; El Garch, F.; Bussiere, A.; Riou, M.; Alsteens, D.; Lins, L.; Baussanne, I.; Dufrene, Y. F.; Brasseur, R.; Decout, J. L.; Mingeot-Leclercq, M. P. The Pseudomonas aeruginosa membranes: a target for a new amphiphilic aminoglycoside derivative? Biochim. Biophys. Acta, Biomembr. 2011, 1808, 1716-1727 10.1016/j.bbamem.2011.01.014
25. Szychowski, J.; Kondo, J.; Zahr, O.; Auclair, K.; Westhof, E.; Hanessian, S.; Keillor, J. W. Inhibition of aminoglycoside-deactivating enzymes APH(3′-IIIa and AAC(6′)-Ii by amphiphilic paromomycin O2-ether analogues ChemMedChem 2011, 6, 1961-1966 10.1002/cmdc.201100346
26. Herzog, I. M.; Green, K. D.; Berkov-Zrihen, Y.; Feldman, M.; Vidavski, R. R.; Eldar-Boock, A.; Satchi-Fainaro, R.; Eldar, A.; Garneau-Tsodikova, S.; Fridman, M. 6-Thioether tobramycin analogues: towards selective targeting of bacterial membranes Angew. Chem., Int. Ed. 2012, 51, 5652-5656 10.1002/anie.201200761
27. Dhondikubeer, R.; Bera, S.; Zhanel, G. G.; Schweizer, F. Antibacterial activity of amphiphilic tobramycin J. Antibiot. 2012, 65, 495-498 10.1038/ja.2012.59
28. Zimmermann, L.; Bussiere, A.; Ouberai, M.; Baussanne, I.; Jolivalt, C.; Mingeot-Leclercq, M. P.; Decout, J. L. Tuning the antibacterial activity of amphiphilic neamine derivatives and comparison to paromamine homologues J. Med. Chem. 2013, 56, 7691-7705 10.1021/jm401148j
29. Van Schepdael, A.; Delcourt, J.; Mulier, M.; Busson, R.; Verbist, L.; Vanderhaeghe, H. J.; Mingeot-Leclercq, M. P.; Tulkens, P. M.; Claes, P. J. New derivatives of kanamycin B obtained by modifications and substitutions in position 6. 1. Synthesis and microbiological evaluation J. Med. Chem. 1991, 34, 1468-1475 10.1021/jm00108a035
30. Fosso, M. Y.; Zhu, H.; Green, K. D.; Fredrick, K.; Garneau-Tsodikova, S. Tobramycin variants with enhanced ribosome-targeting activity ChemBioChem 2015, 16, 1565-1570 10.1002/cbic.201500256
31. Berkov-Zrihen, Y.; Herzog, I. M.; Benhamou, R. I.; Feldman, M.; Steinbuch, K. B.; Shaul, P.; Lerer, S.; Eldar, A.; Fridman, M. Tobramycin and nebramine as pseudo-oligosaccharide scaffolds for the development of antimicrobial cationic amphiphiles Chem.-Eur. J. 2015, 21, 4340-4349 10.1002/chem.201406404
32. Pokrovskaya, V.; Belakhov, V.; Hainrichson, M.; Yaron, S.; Baasov, T. Design, synthesis, and evaluation of novel fluoroquinolone-aminoglycoside hybrid antibiotics J. Med. Chem. 2009, 52, 2243-2254 10.1021/jm900028n
33. Ramirez, M. S.; Tolmasky, M. E. Aminoglycoside modifying enzymes Drug Resist. Updates 2010, 13, 151-171 10.1016/j.drup.2010.08.003
34. Green, K. D.; Chen, W.; Garneau-Tsodikova, S. Effects of altering aminoglycoside structures on bacterial resistance enzyme activities Antimicrob. Agents Chemother. 2011, 55, 3207-3213 10.1128/AAC.00312-11
35. Green, K. D.; Chen, W.; Houghton, J. L.; Fridman, M.; Garneau-Tsodikova, S. Exploring the substrate promiscuity of drug-modifying enzymes for the chemoenzymatic generation of N-acylated aminoglycosides ChemBioChem 2010, 11, 119-126 10.1002/cbic.200900584
36. Green, K. D.; Garneau-Tsodikova, S. Domain dissection and characterization of the aminoglycoside resistance enzyme ANT(3)-Ii/AAC(6′)-IId from Serratia marcescens Biochimie 2013, 95, 1319-1325 10.1016/j.biochi.2013.02.011
37. Chen, W.; Biswas, T.; Porter, V. R.; Tsodikov, O. V.; Garneau-Tsodikova, S. Unusual regioversatility of acetyltransferase Eis, a cause of drug resistance in XDR-TB Proc. Natl. Acad. Sci. U. S. A. 2011, 108, 9804-9808 10.1073/pnas.1105379108
38. Green, K. D.; Pricer, R. E.; Stewart, M. N.; Garneau-Tsodikova, S. Comparative study of Eis-like enzymes from pathogenic and nonpathogenic bacteria ACS Infect. Dis. 2015, 1, 272-283 10.1021/acsinfecdis.5b00036
39. Houghton, J. L.; Biswas, T.; Chen, W.; Tsodikov, O. V.; Garneau-Tsodikova, S. Chemical and structural insights into the regioversatility of the aminoglycoside acetyltransferase Eis ChemBioChem 2013, 14, 2127-2135 10.1002/cbic.201300359
40. Chen, W.; Green, K. D.; Tsodikov, O. V.; Garneau-Tsodikova, S. Aminoglycoside multiacetylating activity of the enhanced intracellular survival protein from Mycobacterium smegmatis and its inhibition Biochemistry 2012, 51, 4959-4967 10.1021/bi3004473
41. Groll, A. H.; Walsh, T. J. Uncommon opportunistic fungi: new nosocomial threats Clin. Microbiol. Infect. 2001, 7, 8-24 10.1111/j.1469-0691.2001.tb00005.x
42. Xie, J. L.; Polvi, E. J.; Shekhar-Guturja, T.; Cowen, L. E. Elucidating drug resistance in human fungal pathogens Future Microbiol. 2014, 9, 523-542 10.2217/fmb.14.18
43. Gullo, A. Invasive fungal infections: the challenge continues Drugs 2009, 69 (Suppl 1) 65-73 10.2165/11315530-000000000-00000
44. Chowdhary, A.; Sharma, C.; Hagen, F.; Meis, J. F. Exploring azole antifungal drug resistance in Aspergillus fumigatus with special reference to resistance mechanisms Future Microbiol. 2014, 9, 697-711 10.2217/fmb.14.27
45. Dolton, M. J.; Ray, J. E.; Chen, S. C.; Ng, K.; Pont, L.; McLachlan, A. J. Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration Antimicrob. Agents Chemother. 2012, 56, 5503-5510 10.1128/AAC.00802-12
46. Meletiadis, J.; Mouton, J. W.; Meis, J. F.; Verweij, P. E. In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates Antimicrob. Agents Chemother. 2003, 47, 106-117 10.1128/AAC.47.1.106-117.2003
47. Shrestha, S. K.; Grilley, M.; Anderson, T.; Dhiman, C.; Oblad, J.; Chang, C. T.; Sorensen, K. N.; Takemoto, J. Y. In vitro antifungal synergy between amphiphilic aminoglycoside K20 and azoles against Candida species and Cryptococcus neoformans Med. Mycol. 2015, 53, 837 10.1093/mmy/myv063
48. Makovitzki, A.; Avrahami, D.; Shai, Y. Ultrashort antibacterial and antifungal lipopeptides Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 15997-16002 10.1073/pnas.0606129103